Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Solcitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 known ✓ | P23458 | 12/20 | 1.00 |
| ▸ | JAK2 | O60674 | 17/20 | 1.00 |
| ▸ | JAK3 | P52333 | 4/20 | 1.00 |
| ▸ | TYK2 | P29597 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2238548 | 0.92 | JAK2 (0.84) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL20435080 | 0.90 | JAK2 (0.82) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2238494 | 0.87 | JAK2 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2238754 | 0.86 | JAK2 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2237152 | 0.86 | JAK2 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2240386 | 0.86 | JAK2 (0.84) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2243221 | 0.86 | JAK2 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2235145 | 0.85 | JAK2 (0.81) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2241762 | 0.85 | JAK2 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2238034 | 0.85 | JAK2 (0.85) | JAK2JAK1JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 498 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | AMPEL BIOSOLUTIONS, LLC (US) | 2026-02-10 | — | — | US | claimed |
| US-20260014156-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A JAK OR OTHER KINASE INHIBITOR | BT BIDCO INC (US) | 2026-01-15 | — | — | US | claimed |
| US-20250336533-A1 | Methods and Systems for Evaluation of Lupus Based on Ancestry-Associated Molecular Pathways | AMPEL BIOSOLUTIONS LLC (US) | 2025-10-30 | — | — | US | claimed |
| EP-4629993-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | Kartos Therapeutics (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250313855-A1 | CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | KITE PHARMA, INC. | 2025-10-09 | — | — | US | claimed |
| EP-4616404-A1 | METHODS AND SYSTEMS FOR EVALUATION OF LUPUS BASED ON ANCESTRY-ASSOCIATED MOLECULAR PATHWAYS | Ampel Biosolutions, LLC (US) | 2025-09-17 | — | — | EP | claimed |
| EP-4599048-A1 | COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS | Trailhead Biosystems Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| EP-4313156-B1 | DISULFIDE-BASED PRODRUG COMPOUNDS | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2025-08-06 | — | — | EP | claimed |
| EP-4583916-A2 | COMPOSITIONS AND METHODS FOR AMELIORATION OF SYMPTOMS ASSOCIATED WITH CLEC16A DYSFUNCTION OR LOSS | The Children's Hospital Of Philadelphia (US) | 2025-07-16 | — | — | EP | claimed |
| WO-2022200347-A1 | DISULFIDE-BASED PRODRUG COMPOUNDS | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2022-09-29 | — | — | WO | claimed |
| EP-4062942-A1 | DISULFIDE-BASED PRODRUG COMPOUNDS | Ludwig-Maximilians-Universität München (DE) | 2022-09-28 | — | — | EP | claimed |
| WO-2022189531-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2022-09-15 | — | — | WO | claimed |
| EP-4056231-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | Fondazione Centro San Raffaele (IT) | 2022-09-14 | — | — | EP | claimed |
| US-11426405-B2 | Inhibition of JAK-STAT signaling inhibits formation of neutrophil extracellular traps (NETs) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-08-30 | — | — | US | claimed |
| US-20220257600-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A JAK OR OTHER KINASE INHIBITOR | GLAS USA LLC | 2022-08-18 | — | — | US | claimed |
| WO-2022159852-A1 | METHODS AND COMPOSITIONS FOR TREATING ADENOID CYSTIC CARCINOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022143628-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR CONDITION ASSOCIATED WITH ANTITUMOR AGENT | 上海岸阔医药科技有限公司 | 2022-07-07 | — | — | WO | claimed |
| WO-2022087313-A1 | METHODS OF TREATING AND PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH GASTROINTESTINAL TRACT DISEASES | PROGENITY, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | JAK1 8/4885JAK2 1/4885JAK3 91/4885 |
| US-20260014156-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A JAK OR OTHER KINASE INHIBITOR | JAK1, JAK3, JAK2 | JAK1 1/4885JAK2 3/4885JAK3 2/4885 |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | SSB, METTL16, TLR9 | JAK1 732/4885JAK2 475/4885JAK3 941/4885 |
| US-20220257600-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A JAK OR OTHER KINASE INHIBITOR | JAK3, JAK1, JAK2 | JAK1 2/4885JAK2 3/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.